The 14th Bioshares Biotech Summit will be held in Queenstown, New Zealand, on 27– 28 July, 2018.
The Summit is a key event for Australian and New Zealand biotech investors. It brings together biotech company decision makers with investment managers and advisors in a collegial setting.
Queenstown is located in a picturesque Alpine setting on New Zealand’s South Island, on the shores of the majestic Lake Wakatipu.
Over the last three months, three listed Australian biotechs have announced they are in the process of being acquired by international competitors – Sirtex Medical for $1.56 billion (by Varian Medical Systems), Viralytics for $502 million (by Merck) and most recently RHS received a bid from PerkinElmer for a price of $25 million.
In light of these pending transactions, the focus of this year’s Summit will be around the Competitive Pressure that stimulates these transactions. However, competitive pressure governs other dynamics in investment and commerce.
Aside from assessing the triggers and the mechanisms behind these individual transactions, the Summit will explore how companies are using competitive pressure in the market place to help strengthen or build dominant market positions.
Another aspect to this theme is the competitive tension that exists in investment markets. What changes investors’ perceptions of a biotech so that demand for stock increases? What moves a stock from the broader radar to one that becomes a ‘must hold’ in an investor’s portfolio?
We invite you to join other biotech investors as well as the CEOs of many listed and unlisted life science companies and benefit from presentations from top level speakers and panellists, which have been the recognised feature of this event for more than a decade.